Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
18 Junio 2024 - 8:00AM
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle
Pharma”), a discovery and development stage specialty
pharmaceutical company focused on improving outcomes for cancer
patients treated with radiation therapy (RT), today announced the
appointment of Timothy Lorber, CPA, as the Company Chief Financial
Officer. The Company’s current Chief Financial Officer, Michael
Vander Hoek, who also serves as our Vice President, Regulatory,
will be transitioning out of his role as Chief Financial Officer
and will assume the Vice President, Regulatory position on a
full-time basis.
Mr. Lorber is a CPA with more than 40 years of professional
finance experience, including 15 years with Legg Mason, Inc. ("Legg
Mason”), one of the world’s larger public global asset management
firms where he served as a Managing Director and Chief Accounting
Officer until its sale in 2020. More recently, Mr. Lorber has
served in leadership roles with several privately held businesses,
overseeing finance, IT and HR functions. Prior to Legg Mason, Mr.
Lorber served as Internal Audit Director of Freddie Mac and has
also worked for several international public accounting firms.
“We are extremely excited to be welcoming Tim Lorber to the
executive team at Shuttle Pharma,” stated Shuttle Pharma’s Chairman
and CEO, Anatoly Dritschilo, M.D. “His deep experience, including
significant involvement with valuations, M&A transactions,
complex financial accounting and Securities Exchange Commission
reporting matters will serve the Company well as we advance our
mission to improve the lives of cancer patients by developing
therapies that are designed to maximize the effectiveness of
Radiation Therapy while limiting the late effects of radiation in
cancer treatment.”
Mr. Lorber will initially serve as the Company’s part-time Chief
Financial Officer until September 9, and, effective September 10,
2024, Mr. Lorber will assume the role of full-time Chief Financial
Officer of the Company. Mr. Vander Hoek will become the full-time
Vice President, Regulatory concurrent with Mr. Lorber’s full-time
appointment as Chief Financial Officer.
“Michael Vander Hoek has been performing two critical roles for
Shuttle for the past four years as both our Chief Financial Officer
and our Vice President of Regulatory. With the Company’s growth and
the planned initiation of the multi-center Phase 2 clinical trial,
Michael will focus his efforts on the successful execution of all
regulatory matters, including management of site enrollment, FDA
relations, and contract research organization activities to ensure
compliance with all matters. I am thankful for Michael’s hard work
as our Chief Financial Officer during the past four plus years and
look forward to his many contributions as we ramp up our clinical
activities,” Dr. Dritschilo concluded.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharma is a discovery and
development stage specialty pharmaceutical company focused on
improving the outcomes for cancer patients treated with radiation
therapy (RT). Our mission is to improve the lives of cancer
patients by developing therapies that are designed to maximize the
effectiveness of RT while limiting the side effects of radiation in
cancer treatment. Although RT is a proven modality for treating
cancers, by developing radiation sensitizers, we aim to increase
cancer cure rates, prolong patient survival and improve quality of
life when used as a primary treatment or in combination with
surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements concerning the development of our company.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the “Risk
Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for
the year ended December 31, 2023, filed with the SEC on March 20,
2024, as well other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof
and, except as required by federal securities laws, Shuttle
Pharmaceuticals specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Shuttle PharmaceuticalsAnatoly
Dritschilo, M.D., CEO240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert
Blum602-889-9700shph@lythampartners.com
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024